Katerina Politi

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer
    Katerina Politi
    Yale University School of Medicine, New Haven, CT, USA
    Clin Cancer Res 18:1490-2. 2012
  2. pmc How genetically engineered mouse tumor models provide insights into human cancers
    Katerina Politi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 29:2273-81. 2011
  3. pmc Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Dis Model Mech 3:111-9. 2010
  4. pmc Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
    Lucia Regales
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e810. 2007
  5. pmc Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
  6. pmc Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
    Jaya Sangodkar
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Invest 122:2637-51. 2012
  7. pmc Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 20:1496-510. 2006
  8. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
  9. pmc Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras
    Katrina Podsypanina
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 105:5242-7. 2008

Collaborators

Detail Information

Publications9

  1. pmc Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer
    Katerina Politi
    Yale University School of Medicine, New Haven, CT, USA
    Clin Cancer Res 18:1490-2. 2012
    ..The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors...
  2. pmc How genetically engineered mouse tumor models provide insights into human cancers
    Katerina Politi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 29:2273-81. 2011
    ..Alternatives to GEMMs, such as chemically induced or spontaneous tumor models, are not discussed in this review...
  3. pmc Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Dis Model Mech 3:111-9. 2010
    ..This preclinical mouse model, therefore, recapitulates the molecular changes responsible for resistance to TKIs in human tumors and holds promise for the discovery of additional mechanisms of drug resistance in lung cancer...
  4. pmc Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
    Lucia Regales
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e810. 2007
    ..The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer...
  5. pmc Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
    ..We sought to improve understanding of this process in order to provide insight into mechanisms of sensitivity and/or resistance to tyrosine kinase inhibitors and to uncover new targets for therapy...
  6. pmc Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
    Jaya Sangodkar
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Invest 122:2637-51. 2012
    ....
  7. pmc Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
    Katerina Politi
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 20:1496-510. 2006
    ..These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations...
  8. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    ..Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity...
  9. pmc Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras
    Katrina Podsypanina
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 105:5242-7. 2008
    ..These results demonstrate that tumor viability is maintained by each gene in a combination of oncogenes and that targeted approaches will also benefit from combination therapies...

Research Grants6

  1. Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
    KATERINA ABIGAIL POLITI; Fiscal Year: 2010
    ..Finally, we will explore the striking appearance of immune cells in mouse lung tumors, in an effort to understand how such cells arrived in the lung tissue and what functions they serve to promote or retard tumor development. ..
  2. Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
    Harold Varmus; Fiscal Year: 2006
    ....
  3. Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
    Harold Varmus; Fiscal Year: 2007
    ....
  4. Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
    Harold Varmus; Fiscal Year: 2009
    ....
  5. Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
    Harold Varmus; Fiscal Year: 2009
    ..PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..